What is LOPJLB’s current signal on RPTX?

LOPJLB’s latest quantitative signal on Repare Therapeutics Inc. (RPTX) is BUY in a BULL regime. Signals are updated daily.

What market regime is RPTX in?

Repare Therapeutics Inc. (RPTX) is currently classified in the BULL HMM market regime on LOPJLB.

Repare Therapeutics Inc. (RPTX)

COMPARE

Healthcare · Biotechnology · NASDAQ · CA

$2.65+0.00%Close

BUYBULL · day 29

RANGE

DATA 2026-01-28

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONE

Key stats

Market cap: $114M
Beta: 0.96

P/E (TTM): -8.43

1W: +2.32%
1M: +3.11%

vs SPY 1W: +1.16%
vs SPY 1M: +0.12%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Repare Therapeutics Inc. is a precision oncology biopharmaceutical company in the clinical stage, focused on discovering and developing innovative therapies. Operating across Canada and the United States, the company leverages a synthetic lethality approach to identify new…

Employees: 129
Headquarters: CA
Founded: 2020
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 43.1M
Float: 80.4%

reparerx.com ↗

Key executives

Steve Forte — President, Chief Financial Officer, Chief Executive Officer & Director

Michael Zinda — Executive Vice President & Chief Scientific Officer

Daniel Durocher — Co-Founder

SEC filings

EDGAR · CIK 18081580 · RPTX

Analyst consensus

Buy

Bullish777.8%

Neutral222.2%

Bearish00.0%

L $3.00Avg $16.00H $30.00

Target$16.00+503.77%

Last$2.65

FAQ

What is LOPJLB’s current signal on RPTX?: LOPJLB’s latest quantitative signal on Repare Therapeutics Inc. (RPTX) is BUY in a BULL regime. Signals are updated daily.
What market regime is RPTX in?: Repare Therapeutics Inc. (RPTX) is currently classified in the BULL HMM market regime on LOPJLB.
What does Repare Therapeutics Inc. (RPTX) do?: Repare Therapeutics Inc. is a precision oncology biopharmaceutical company in the clinical stage, focused on discovering and developing innovative therapies. Operating across Canada and the United States, the company leverages a synthetic lethality approach to identify new treatments. Central to their efforts is the proprietary, genome-wide, and CRISPR-enabled SNIPRx platform, which systematica…

Key stats

Prediction markets

Company news

FAQ